drugset / Trial / NCT02281292
A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the initial safety of intravitreal (IVT) LKA651 and potential for use alone or in combination with Ranibizumab ophthalmic solution (Lucentis®) for the treatment of Diabetic Macular Edema (DME) in patients with symptomatic disease.
Timeline
- Start
- 2015-12
- Primary completion
- 2017-06
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LKA651 | Unknown | — | Intravitreal |
| Background | Ranibizumab | Monoclonal antibody | 0.5 mg | — |